Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting
Sanjib Saha(University of Iowa), Fredrik Liedberg(Lund University), James W.F. Catto(University of Sheffield), Christel Häggström(Uppsala University), Gottfrid Sjödahl(Lund University), John D. Kelly(University College Hospital), Lars Holmberg(Uppsala University), Anders Ullén(Inserm), Ulf‐G. Gerdtham(Malmö University)
Cited by 0
Related Papers
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
|European Urology|2019|1.4k
A Molecular Taxonomy for Urothelial Carcinoma
|Clinical Cancer Research|2012|1k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
Changes in circulating microRNA levels associated with prostate cancer
|British Journal of Cancer|2012|717